Aprea Therapeutics, Inc

Exeltis USA Inc, based in Florham Park, NJ, is a leading provider of women's health products, dedicated to empowering women to lead their healthiest lives. With a commitment to delivering extraordinary solutions for evolving women's health needs, Exeltis collaborates and innovates to meet emerging healthcare challenges and provide unique formulations that support women at every stage of life. Driven by a vision of excellence, Exeltis is fearless in its pursuit of better health options for patients. The company not only offers exceptional products but also fosters professional development opportunities for healthcare professionals, while fulfilling social responsibilities through its partnership with the Mundo Sano non-profit foundation. With a focus on collaboration, innovation, and social impact, Exeltis is at the forefront of women's health expertise.Generated from the website

Taiho Oncology Inc, located in Princeton, NJ, is dedicated to advancing cancer treatment through innovative drug discovery and development. The company focuses on creating therapies that improve patient outcomes in oncology, highlighting its commitment to sustainability and collaboration within the healthcare industry. With a robust portfolio of products and a pipeline of promising therapies, Taiho Oncology is actively engaged in addressing unmet medical needs in the field of cancer care. Their collaborative efforts with other biotechnology firms demonstrate a strategic approach to enhancing treatment options for patients worldwide. Generated from the website

Carisma Therapeutics Inc. is a Philadelphia-based biotech company that is revolutionizing cancer treatment through the development of CAR-Macrophages, a groundbreaking approach to immunotherapy. By engineering monocytes and macrophages to attack tumors, Carisma's innovative cellular therapies have the potential to deliver long-term anti-tumor immunity and significantly improve patient outcomes. With a focus on leveraging advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy, Carisma's unique therapeutic approach engages both the innate and adaptive immune systems to launch a multi-pronged attack on tumors. By addressing key challenges faced by current cell therapies, such as tumor infiltration, immunosuppressive tumor microenvironments, and antigen heterogeneity, Carisma is at the forefront of developing life-changing treatments for patients with cancer and other serious disorders.Generated from the website